GLP-1 Receptor Agonists Significantly Reduce Cerebrovascular Events, Hospitalizations, and Mortality in Obstructive Sleep Apnea Patients
Background
Obstructive Sleep Apnea (OSA) is a prevalent condition strongly linked to obesity and increased risk of adverse cerebrovascular outcomes. Despite the known benefits of glucagon-like peptide-1 receptor agonists (GLP-1As) in diabetes and obesity, their long-term impact on OSA patients, particularly regarding cerebrovascular health and overall survival, has remained largely uncharacterized. Current standard-of-care for OSA often involves CPAP, but adjunctive therapies that address systemic comorbidities and improve long-term outcomes are critically needed.
Study Design
This retrospective cohort study utilized the TriNetX US Collaborative Network, analyzing data from January 1st 2016 to December 31st 2025. Researchers identified adults with OSA and defined exposure as the initiation of a GLP-1A within six months before or one month after OSA diagnosis. Propensity score matching was performed 1:1 to create comparable cohorts. Outcomes, assessed at 1, 3, and 5 years, included ischemic stroke, intracranial hemorrhage, emergency department visits, inpatient hospitalizations, and all-cause mortality. Statistical analyses involved Kaplan-Meier curves and Cox proportional hazards models. Subgroup analyses were also conducted for CPAP-restricted patients and those specifically treated with tirzepatide.
Results
After rigorous propensity score matching, 438,844 patients were included in each cohort, totaling 877,688 individuals. Across 1-, 3-, and 5-year follow-up periods, GLP-1A exposure was consistently associated with significantly lower hazards for all assessed outcomes (all p<0.001). Specifically, GLP-1A use reduced the hazard of ischemic stroke (HRs, 0.75, 0.83, and 0.87), and intracranial hemorrhage (HRs, 0.44, 0.56, and 0.61). Healthcare utilization also saw substantial reductions, with emergency department visits decreasing (HRs, 0.77, 0.86, and 0.87) and inpatient hospitalizations falling (HRs, 0.59, 0.67, and 0.69).
Key Findings
- GLP-1A exposure reduced ischemic stroke hazard by 13-25% across 1-5 years (HRs 0.75-0.87, p<0.001).
- Intracranial hemorrhage hazard was cut by 39-56% with GLP-1As over 1-5 years (HRs 0.44-0.61, p<0.001).
- All-cause mortality hazard decreased by 46-62% in GLP-1A users across 1-5 years (HRs 0.38-0.54, p<0.001).
- Emergency department visits were reduced by 13-23% (HRs 0.77-0.87, p<0.001).
- Inpatient hospitalizations dropped by 31-41% (HRs 0.59-0.69, p<0.001).
Why It Matters
This large real-world analysis suggests that GLP-1 receptor agonists could play a significant role as an adjunct to standard OSA management, extending beyond their established benefits in weight loss and diabetes. The observed reductions in cerebrovascular events, healthcare utilization, and all-cause mortality highlight a potential for GLP-1As to improve long-term prognosis for OSA patients. This finding implies that clinicians and individuals managing OSA should consider GLP-1A therapy for its broader protective effects, particularly in those with associated cardiometabolic risks. While these findings are hypothesis-generating, they underscore the need for prospective clinical trials to validate GLP-1As as a comprehensive therapeutic strategy for OSA.
glp-1-agonist
obstructive-sleep-apnea
cerebrovascular-disease
mortality
real-world-data
cohort-study